Table 6.
Multivariate analysis for overall survival in patients who received 56–60 Gy.
| Variant | Hazard ratio | 95% CI (Lower) | 95% CI (Upper) | p-value |
|---|---|---|---|---|
| Age at diagnosis, n | ||||
| <40 y | 1 | |||
| 40–64 y | 1.557 | 0.714 | 3.397 | 0.266 |
| >64 y | 1.985 | 0.856 | 4.599 | 0.110 |
| Extent of surgical resection, n | ||||
| Gross total resection | 1 | |||
| Subtotal resecction | 1.673 | 1.023 | 2.739 | 0.041 |
| Biopsy | 1.096 | 0.708 | 1.698 | 0.680 |
| Comorbidities at diagnosis, n | ||||
| Ischemic heart disease | 2.838 | 1.202 | 6.701 | 0.017 |
| No. of adjuvant Temozolomide cycles*, n | ||||
| 0 | 1 | |||
| 1–3 | 0.695 | 0.317 | 1.522 | 0.363 |
| 4–6 | 0.653 | 0.293 | 1.453 | 0.296 |
| 7–9 | 0.329 | 0.134 | 0.805 | 0.015 |
| ≥10 | 0.123 | 0.052 | 0.288 | 0.000 |
| Patients who switched to 2nd line therapy | ||||
| Yes | 1 | |||
| No | 0.457 | 0.319 | 0.654 | 0.000 |
| Waiting time until concomitant therapy with RT + TMZ, d | ||||
| <28 days | 1 | |||
| 28–42 days | 0.910 | 0.572 | 1.449 | 0.692 |
| ≥42 days | 0.568 | 0.358 | 0.899 | 0.016 |
| *Post concomitant therapy with RT + TMZ. | ||||
Hazard ratio (HR) less than 1 – better overall survival, > 1 – worse overall survival; P-value < 0.05 – statistically significant.